UNCY Company Profile and Key Details

Q: Who are the executives of UNCY?

Mr. Douglas Jermasek M.B.A.Vice President of Marketing & StrategyMr. John W. Townsend CPAChief Financial OfficerDr. Shalabh K. Gupta M.D., MPAFounder, Chairman, Chief Executive Officer & PresDr. Pramod Gupta Ph.D.Executive Vice President of Pharmaceutical & Bus. Operations

NASDAQ : UNCY

Unicycive Therapeutics

$5.77

0.18+3.22%

At Close 4:00 PM

64.46

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Unicycive Therapeutics, Inc. (UNCY) stock surged +3.22%, trading at $5.77 on NASDAQ, up from the previous close of $5.59. The stock opened at $5.60, fluctuating between $5.46 and $5.78 in the recent session.

Stock Snapshot

5.59

Prev. Close

101.91M

Market Cap

5.46

Day Low

-1.68

P/E Ratio

-3.44

EPS (TTM)

-0.53

Cash Flow per Share

5.6

Open

17.66M

Number of Shares

5.78

Day High

73.65%

Free Float in %

-0.11

Book Value

276.64K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 31, 2025	5.60	5.78	5.45	5.77	281.94K
Dec 30, 2025	5.91	6.03	5.45	5.59	576.36K
Dec 29, 2025	6.25	6.30	5.93	5.93	524.69K
Dec 26, 2025	5.93	6.08	5.76	6.07	198.19K
Dec 24, 2025	5.77	5.92	5.69	5.86	115.91K
Dec 23, 2025	5.84	5.92	5.70	5.74	180.63K
Dec 22, 2025	5.57	5.85	5.54	5.85	256.29K
Dec 19, 2025	5.45	5.58	5.37	5.56	389.94K
Dec 17, 2025	5.88	5.91	5.42	5.45	648.68K
Dec 16, 2025	5.89	6.05	5.85	5.88	212.22K
Dec 15, 2025	6.31	6.31	5.86	5.88	379.74K
Dec 12, 2025	6.41	6.57	6.20	6.23	249.14K
Dec 11, 2025	6.59	6.63	6.32	6.41	301.51K
Dec 10, 2025	6.55	6.69	6.31	6.59	310.04K
Dec 09, 2025	6.54	6.95	6.48	6.52	370.34K
Dec 08, 2025	6.28	6.65	6.06	6.58	455.59K
Dec 05, 2025	6.57	6.60	6.20	6.23	436.26K
Dec 04, 2025	6.23	6.56	6.14	6.50	307.3K
Dec 03, 2025	5.91	6.21	5.91	6.17	361.78K
Dec 02, 2025	6.06	6.26	5.77	5.86	373.13K

Contact Details

Los Altos, CA 94022

United States

https://www.unicycive.com 650 351 4495

About Company

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Stock Peers

ARGX

3.05+0.36%

argenx SE$840.95 REGN

-2.07-0.27%

Regeneron Pharmaceuticals, Inc.$771.87 MDGL

-1.39-0.24%

Madrigal Pharmaceuticals, Inc.$582.34 UTHR

-8.94-1.80%

United Therapeutics Corporation$487.25 VRTX

-0.38-0.08%

Vertex Pharmaceuticals Incorporated$453.36 ALNY

0.4+0.10%

Alnylam Pharmaceuticals, Inc.$397.65 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-2.28-0.77%

Praxis Precision Medicines, Inc.$294.74 KRYS

-1.34-0.54%

Krystal Biotech, Inc.$246.54 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) closed at $5.77 USD, gaining $0.18 (3.22%) from the previous close of $5.59. The stock is currently mid-range between its 52-week high and low $3.71 and $11.00. With a market capitalization of about $101.91 million, Unicycive Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.83). Key stats such as the average daily volume over the past year has been around 413.67 thousand shares, volume is running light vs its 52-week average. Headquartered in Los Altos, CA, Unicycive Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shalabh K. Gupta, the company employs approximately 22 people and listed since July 12, 2021. Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -4.0%, SMA50 4.41%, SMA200 8.16%). The stock’s 14-day RSI is 49.58 (neutral), while the ATR of 0.37 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -47.55% below its high and over 55.53% above its low. Average 10-day trading volume of 304.86 thousand shares is below the 3-month average of 410.64 thousand, indicating normal recent market interest.

Valuation Metrics

Unicycive Therapeutics, Inc. trades at a P/E ratio of -3.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.77 suggesting the stock is closer to book value. The P/FCF stands at -3.4, also below market averages.

Dividend & Fair Value

Unicycive Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.79. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Unicycive Therapeutics, Inc. generated EPS of -$3.25 over the past year. Five-year average earnings growth is -31.8%. The latest quarter delivered EPS of -$0.33. The next quarter is forecast at -$0.43. Next year's EPS is expected at $66.05. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $4.00. The high target offers 281.28% upside. The low target suggests -30.68% downside. The mean target is $10.29. This offers 78.34% upside. Unicycive Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -43.6%. The prior quarter beat by -25.71%. Over the last six quarters, Apple has recorded several small beats. These include 50.0% in May 13, 2024.

Shareholding & Insider Activity

Unicycive Therapeutics, Inc. has 17.66 million shares outstanding. The public float is 13.01 million shares, elevated short interest at 7.55% of float. This equals 1.28 million shares. The short ratio is 2.79 days. Institutional investors hold 32.2% of the float. Insiders own 3.56%.

Financial & Profitability Overview

Over the trailing twelve months, Unicycive Therapeutics generated $675.00K in revenue, or $0.03 per share. Gross margin was 57.93%, operating margin -3077.63%, and net profit margin -4525.04%. Returns are negative, with ROA at -215.24% and ROE at 801.89%.
On valuation metrics, Unicycive Therapeutics trades at a P/E of -3.11, P/S of 0.00 and P/B of 2.77. The current ratio is 3.83 and quick ratio is 3.83. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -112.58.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Unicycive Therapeutics posted revenue of $675.00K, down slightly from $951.00K in the prior quarter. Gross profit was $391.00K (margin 57.93%). Operating income was - $20.77M (margin -3077.6%). Net income was- $30.54M (EPS - $1.24).
The company ended the quarter with $9.70M in cash and short-term investments, a total debt of $811.00K, and net debt of - $8.89M. Total assets were $14.19M, with equity of - $3.81M. Financials further reflected weakness, with operating cash flow of - $18.28M, free cash flow of - $18.30M, and capital expenditures of - $12.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Unicycive Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.43%, with price expected at $5.63 by January 13, 2026, within a range of $5.24 to $6.01 3-Month Outlook: Projected fall of -69.5%, reaching $1.76 by March 30, 2026, with a range of $1.47 to $2.01. 1-Year Outlook: Projected gain of 289.43%, with price at $22.47 by December 30, 2026, within a range of $4.23 to $34.59.

Key Takeaways

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares are down -27.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Unicycive Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.10, suggesting 23.05% upside. Our AI forecast model points to short-term weakness (-2.43% over two weeks), a medium-term fall (-69.5% over three months), and a longer-term gain (289.43% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Unicycive Therapeutics, Inc. (UNCY) stock price?

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) stock price is $5.77 in the last trading session. During the trading session, UNCY stock reached the peak price of $5.78 while $5.46 was the lowest point it dropped to. The percentage change in UNCY stock occurred in the recent session was 3.22% while the dollar amount for the price change in UNCY stock was $0.18.

UNCY's industry and sector of operation?

The NASDAQ listed UNCY is part of Biotechnology industry that operates in the broader Healthcare sector. Unicycive Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of UNCY?

Mr. Douglas Jermasek M.B.A.
Vice President of Marketing & Strategy
Mr. John W. Townsend CPA
Chief Financial Officer
Dr. Shalabh K. Gupta M.D., MPA
Founder, Chairman, Chief Executive Officer & Pres
Dr. Pramod Gupta Ph.D.
Executive Vice President of Pharmaceutical & Bus. Operations

How UNCY did perform over past 52-week?

UNCY's closing price is 55.53% higher than its 52-week low of $3.71 where as its distance from 52-week high of $11.00 is -47.55%.

How many employees does UNCY have?

Number of UNCY employees currently stands at 22.

Link for UNCY official website?

Official Website of UNCY is: https://www.unicycive.com

How do I contact UNCY?

UNCY could be contacted at phone 650 351 4495 and can also be accessed through its website. UNCY operates from 4300 El Camino Real, Los Altos, CA 94022, United States.

How many shares of UNCY are traded daily?

UNCY stock volume for the day was 276.64K shares. The average number of UNCY shares traded daily for last 3 months was 413.67K.

What is the market cap of UNCY currently?

The market value of UNCY currently stands at $101.91M with its latest stock price at $5.77 and 17.66M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	22
Beta	1.83
Sales or Revenue	$675.00K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

UNCY Company Profile and Key Details

Unicycive Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Valuation Metrics